Adverum Biotechnologies (ADVM) Competitors $2.77 -0.07 (-2.46%) Closing price 04:00 PM EasternExtended Trading$2.76 0.00 (-0.18%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. DSGN, UPXI, MDWD, BTMD, LRMR, CGC, CRGX, ACIU, NMRA, and FDMTShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Design Therapeutics (DSGN), Upexi (UPXI), MediWound (MDWD), biote (BTMD), Larimar Therapeutics (LRMR), Canopy Growth (CGC), CARGO Therapeutics (CRGX), AC Immune (ACIU), Neumora Therapeutics (NMRA), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors Design Therapeutics Upexi MediWound biote Larimar Therapeutics Canopy Growth CARGO Therapeutics AC Immune Neumora Therapeutics 4D Molecular Therapeutics Adverum Biotechnologies (NASDAQ:ADVM) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk. Does the media prefer ADVM or DSGN? In the previous week, Adverum Biotechnologies and Adverum Biotechnologies both had 1 articles in the media. Adverum Biotechnologies' average media sentiment score of 0.94 beat Design Therapeutics' score of 0.93 indicating that Adverum Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adverum Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ADVM or DSGN? Adverum Biotechnologies has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Is ADVM or DSGN more profitable? Design Therapeutics' return on equity of -22.85% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -130.53% -66.31% Design Therapeutics N/A -22.85%-22.02% Which has stronger earnings and valuation, ADVM or DSGN? Design Therapeutics has lower revenue, but higher earnings than Adverum Biotechnologies. Design Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$1M57.87-$130.93M-$6.40-0.43Design TherapeuticsN/AN/A-$49.59M-$0.99-4.02 Do institutionals & insiders believe in ADVM or DSGN? 48.2% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 6.0% of Adverum Biotechnologies shares are held by insiders. Comparatively, 31.2% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend ADVM or DSGN? Adverum Biotechnologies presently has a consensus price target of $23.80, suggesting a potential upside of 759.21%. Design Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 0.50%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Adverum Biotechnologies is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryDesign Therapeutics beats Adverum Biotechnologies on 7 of the 12 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.33M$2.91B$5.52B$9.41BDividend YieldN/A2.45%3.80%4.04%P/E RatioN/A19.8828.0419.84Price / Sales57.87305.11429.5399.59Price / CashN/A43.1635.8457.94Price / Book0.817.678.125.65Net Income-$130.93M-$55.28M$3.25B$258.00M7 Day Performance9.06%2.50%0.97%2.09%1 Month Performance20.96%11.70%7.36%11.13%1 Year Performance-70.78%4.89%31.31%18.40% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.4165 of 5 stars$2.77-2.5%$23.80+759.2%-67.7%$59.33M$1M-0.43190DSGNDesign Therapeutics0.4659 of 5 stars$4.00+2.0%$4.00-9.9%$227.08MN/A-4.0440News CoverageUPXIUpexi1.7585 of 5 stars$5.96+10.6%$16.00+168.5%-13.8%$225.97M$16.56M0.00130News CoverageGap UpHigh Trading VolumeMDWDMediWound1.6367 of 5 stars$20.47+2.2%$31.80+55.3%-1.4%$221.24M$19.21M-9.7980Positive NewsBTMDbiote3.3269 of 5 stars$4.04-1.0%$8.00+98.0%-49.5%$221.03M$199.38M6.62194LRMRLarimar Therapeutics2.2663 of 5 stars$3.45+2.1%$18.50+436.2%-67.1%$220.90MN/A-2.3230Positive NewsCGCCanopy Growth0.4488 of 5 stars$1.17+3.5%N/A-85.1%$215.13M$225.65M-0.293,150Positive NewsCRGXCARGO Therapeutics2.3335 of 5 stars$4.59flat$15.40+235.5%-74.0%$211.65MN/A-0.99116High Trading VolumeACIUAC Immune2.1805 of 5 stars$2.08+2.0%$12.00+476.9%-42.5%$208.85M$31.02M-3.59140Positive NewsNMRANeumora Therapeutics2.3949 of 5 stars$1.27-1.6%$7.50+490.6%-85.6%$205.42MN/A-0.79108Positive NewsAnalyst ForecastGap UpFDMT4D Molecular Therapeutics2.2164 of 5 stars$4.38+2.3%$29.56+574.8%-76.0%$202.93M$40K-1.38120 Related Companies and Tools Related Companies DSGN Alternatives UPXI Alternatives MDWD Alternatives BTMD Alternatives LRMR Alternatives CGC Alternatives CRGX Alternatives ACIU Alternatives NMRA Alternatives FDMT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.